Gilead Sciences Live Stock Price Today, Share Analysis and Chart

Name: Gilead Sciences, Inc.: Is Infosys Ltd. worth buying?
Item: Gilead Sciences, Inc.
Rating: 2.290569375
Author: Trendlyne DVM scores

Mid-range Performer

about

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

127.88 4.04 (3.26%)

19.7M

XNAS Volume

High volume today

XNAS 26 Jun, 2026 5:30 PM (EDT)

Medium Financial Strength

44.4 / 100

Mid Valuation

47.2 / 100

Technically Neutral

47.2 / 100

Mid-range Performer These stocks have average quality, financial and technical momentum, indicating a mid range performer View Similar Embed DVM

158

1Yr Price target upside is 23%

28 analysts

Gilead Sciences Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Gilead Sciences Live Stock Price Today, Share Analysis and Chart

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

High volume today

SWOT Analysis

Gilead Sciences Live Price Chart